Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06955468 · ClinicalTrials.gov registry record · NA
Evaluating a Bidirectional Priming Intervention for Goals-of-care Communication in Oncology
A NA study of Lung Cancers and Gastrointestinal Cancers, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06955468 is a NA study of Lung Cancers and Gastrointestinal Cancers that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 40 participants, below the 174-participant average among 5 other Lung Cancers trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06955468, a NA study of Lung Cancers and Gastrointestinal Cancers, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot study will evaluate whether an intervention aimed at hospitalized patients with advanced lung and gastrointestinal cancers can help facilitate goals-of-care (GOC) communication with their oncologists after discharge. While GOC communication is a recommended component of routine oncology care, many patients with solid cancers do not have the opportunity to talk with their oncologist about their goals and end-of-life preferences. Prior research has shown that a systematic method of prompting GOC communication with at-risk patients would address a key barrier to timely GOC communication and ensure that patients receive care that is in line with their personal preferences. This trial will enroll 80 participants, who will be randomized 1:1 to either an intervention or a control group. Participants in the intervention group will complete a short survey regarding their goals, preferences, and disease understanding. Survey responses will be shared with each participant's outpatient oncology team. Oncologists will subsequently receive a nudge in the electronic medical record reminding them of key survey responses and encouraging them to discuss them at the patient's first clinic visit after hospital discharge. The primary feasibility outcome is intervention completion rate and the primary clinical outcome is GOC documentation within 30 days of discharge in the intervention group compared to the control group.
Conditions Studied
Interventions
- BEHAVIORAL Priming Survey
Study Locations (1)
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-07-21 |
| Est. Completion | 2026-03-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06955468
The ClinicalTrials.gov registry entry for NCT06955468 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 174-participant average among 5 other Lung Cancers trials with a reported enrollment target (77% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lung Cancers appearing as the primary indexed condition, and to 1 intervention - of which Priming Survey is the first listed.
NCT06955468 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06955468 about?
NCT06955468 is a clinical study titled "Evaluating a Bidirectional Priming Intervention for Goals-of-care Communication in Oncology". This pilot study will evaluate whether an intervention aimed at hospitalized patients with advanced lung and gastrointestinal cancers can help facilitate goals-of-care (GOC) communication with their oncologists after discharge. While GOC communication is a recommended component of routine oncology ...
What is the current status of trial NCT06955468?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2025-07-21. Estimated completion is 2026-03-01.
What conditions does trial NCT06955468 study?
This clinical trial studies the following conditions: Lung Cancers, Gastrointestinal Cancers.
What interventions are being tested in trial NCT06955468?
The interventions under investigation include: Priming Survey (BEHAVIORAL).
Who is sponsoring clinical trial NCT06955468?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06955468 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Bright Light Therapy on Sleep Health in Lung Cancer Patients
RECRUITING · NA
-
Erector Spinae Versus Intercostal Nerve Blocks With Liposomal Bupivacaine for Analgesia in Thoracic Surgery
RECRUITING · Phase 3
-
Rapid Autopsy and Procurement of Cancer Tissue
RECRUITING
-
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
RECRUITING · Phase 1
-
A Single Dose, Open-Label, Dose-escalation Study of the Safety and Imaging Characteristics of LS301-IT for Intraoperative Imaging of Lung Cancer
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.